James Xu is a partner in Goodwin’s Technology Companies & Life Sciences group. Mr. Xu’s practice concentrates on capital markets transactions, focusing on initial public offerings, as well as securities law reporting and compliance. In his practice, Mr. Xu represents a wide variety of companies and investment banks in the technology and life sciences industries. In addition, Mr. Xu counsels clients in private financings, mergers and acquisitions, governance and other general corporate matters. He joined Goodwin in 2010.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. Xu’s recent transactional experience include:

  • Aerpio Pharmaceuticals’s listing as a public company through a reverse merger transaction and a concurrent $40 million private placement
  • Allena Pharmaceuticals in its $75 million initial public offering
  • AquaVenture Holdings in its $117 million initial public offering
  • BioAmber in several follow on public offerings raising an aggregate of $120.1 million
  • Borderfree in its $80 million initial public offering and subsequent $395 million sale to Pitney Bowes
  • Esperion Therapeutics in several follow-on public offerings raising an aggregate of $450 million
  • Mimecast in its $77.5 million initial public offering and its $66 million secondary public offering
  • Neos Therapeutics in several follow-on public offerings raising an aggregate of $55 million
  • ProQR Therapeutics in its $97.5 million initial public offering, several follow-on public offerings raising an aggregate of $26 million and the establishment of its at-the-market facility
  • Ra Pharmaceuticals in its $91.6 million initial public offering
  • scPharmaceuticals in its $90 million initial public offering
  • Vascular Biogenics in its $40 million initial public offering, several follow-on public offerings raising an aggregate of $39 million and the establishment of its at-the-market facility
  • Virtusa Corporation in its $91 million follow-on public offering and its $108 million private placement of preferred stock
  • The underwriting syndicate in Edge Therapeutics’ $92 million initial public offering
  • The underwriting syndicate in InflaRx’s $100 million initial public offering
  • The underwriting syndicate in Innocoll AG’s $59 million initial public offering and its subsequent follow-on public offering raising an aggregate of $70 million
  • The underwriting syndicate in Nivalis Therapeutics’ $88 million initial public offering
  • The underwriting syndicate in Paylocity’s $138 million initial public offering
  • The underwriting syndicate in Tokai Pharmaceuticals’ $97 million initial public offering
Professional Experience

Prior to joining Goodwin, Mr. Xu was a Litigation Fellow at the Lawyers’ Committee for Civil Rights Under Law of the Boston Bar Association, practicing civil rights litigation in the areas of employment, housing and racial violence.

Mr. Xu co-authored “Consistency of Confusion? A Fifteen-Year Revisiting of Barton Beebe’s Empirical Analysis of Multifactor Tests for Trademark Infringement,” which was published in the Stanford Technology Law Review (2010 Stan. Tech. L. Rev. 3).

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2009
Harvard Law School
B.A., 2006
University of California, Davis

Admissions

Bar

Massachusetts
Get In Touch
German Translation
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师